View in EDS

Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.

Saved in:
Bibliographic Details
Title: Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.
Authors: Zhou, Qing1 (AUTHOR), Xu, Chong-Rui1 (AUTHOR), Cheng, Ying2 (AUTHOR), Liu, Yun-Peng3 (AUTHOR), Chen, Gong-Yan4 (AUTHOR), Cui, Jiu-Wei5 (AUTHOR), Yang, Nong6 (AUTHOR), Song, Yong7 (AUTHOR), Li, Xiao-Ling8 (AUTHOR), Lu, Shun9 (AUTHOR), Zhou, Jian-Ying10 (AUTHOR), Ma, Zhi-Yong11 (AUTHOR), Yu, Shi-Ying12 (AUTHOR), Huang, Cheng13 (AUTHOR), Shu, Yong-Qian14 (AUTHOR), Wang, Zhen1 (AUTHOR), Yang, Jin-Ji1 (AUTHOR), Tu, Hai-Yan1 (AUTHOR), Zhong, Wen-Zhao1 (AUTHOR), Wu, Yi-Long1 (AUTHOR) syylwu@live.cn
Source: Cancer Cell. Sep2021, Vol. 39 Issue 9, p1279-1279. 1p.
Database: Academic Search Ultimate
Description
ISSN:15356108
DOI:10.1016/j.ccell.2021.07.005